Llanos et al., 2013 - Google Patents
Tolerogenic dendritic cells as a therapy for treating lupusLlanos et al., 2013
View PDF- Document ID
- 6562857216623888079
- Author
- Llanos C
- Mackern-Oberti J
- Vega F
- Jacobelli S
- Kalergis A
- Publication year
- Publication venue
- Clinical immunology
External Links
Snippet
Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder that is characterized by the over production of auto-antibodies against nuclear components. Thus, SLE patients have increased morbidity and, mortality compared to healthy individuals. Available therapies …
- 210000004443 Dendritic Cells 0 title abstract description 133
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Llanos et al. | Tolerogenic dendritic cells as a therapy for treating lupus | |
| Coutant et al. | Altered dendritic cell functions in autoimmune diseases: distinct and overlapping profiles | |
| Fung et al. | Activation of group 2 innate lymphoid cells alleviates aging-associated cognitive decline | |
| Farrugia et al. | The role of toll‐like receptors in autoimmune diseases through failure of the self‐recognition mechanism | |
| Boulé et al. | Toll-like receptor 9–dependent and–independent dendritic cell activation by chromatin–immunoglobulin G complexes | |
| Tha-In et al. | Modulation of the cellular immune system by intravenous immunoglobulin | |
| Mathan et al. | Human plasmacytoid dendritic cells: from molecules to intercellular communication network | |
| Shachar et al. | The dual roles of inflammatory cytokines and chemokines in the regulation of autoimmune diseases and their clinical implications | |
| Oon et al. | Targeted therapeutics in SLE: emerging strategies to modulate the interferon pathway | |
| Döring et al. | Auto-antigenic protein-DNA complexes stimulate plasmacytoid dendritic cells to promote atherosclerosis | |
| Panda et al. | Plasmacytoid dendritic cells in autoimmunity | |
| Decker et al. | Nucleosome, the main autoantigen in systemic lupus erythematosus, induces direct dendritic cell activation via a MyD88-independent pathway: consequences on inflammation | |
| Wu et al. | TLR-activated plasmacytoid dendritic cells inhibit breast cancer cell growth in vitro and in vivo | |
| Comabella et al. | Targeting dendritic cells to treat multiple sclerosis | |
| Liu et al. | IFNα inducible models of murine SLE | |
| Yarchoan et al. | Effects of B cell–activating factor on tumor immunity | |
| Mackern‐Oberti et al. | Contribution of dendritic cells to the autoimmune pathology of systemic lupus erythematosus | |
| Vogel et al. | JAK1 signaling in dendritic cells promotes peripheral tolerance in autoimmunity through PD-L1-mediated regulatory T cell induction | |
| Mochizuki et al. | Notch and inflammatory T-cell response: new developments and challenges | |
| Meng et al. | DLL4+ dendritic cells: key regulators of Notch Signaling in effector T cell responses | |
| Kirchhof et al. | The immunopathology of cutaneous lupus erythematosus | |
| Mok et al. | Recent advances and current state of immunotherapy in systemic lupus erythematosus | |
| Crow | Interferon pathway activation in systemic lupus erythematosus | |
| Seitz et al. | Dendritic cells in systemic lupus erythematosus | |
| Simpson et al. | Plasmacytoid dendritic cells respond directly to apoptotic cells by secreting immune regulatory IL-10 or IFN-α |